Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anette McGowan

Clinical Nurse Specialist, Neuroscience Rancho Mirage, CA Nurse Practitioner

NPI 1962478479 CMS profile 10688459

34490 Bob Hope Dr, Rancho Mirage, CA 92270

Open in the dashboard

General payments

$28,354

1,082 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anette McGowan of Rancho Mirage, CA is reported in the CMS Open Payments database as having received $28,354 across 1,082 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,539 209
2024 General $5,590 209
2023 General $6,069 236
2022 General $6,202 251
2021 General $4,954 177

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anette McGowan
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Anette McGowan were reported at $5,539. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Anette McGowan California median Middle half National median
2019 $0 $161 $50–$652 $163
2020 $0 $114 $34–$392 $114
2021 $4,954 $137 $41–$509 $132
2022 $6,202 $152 $48–$573 $149
2023 $6,069 $162 $50–$581 $160
2024 $5,590 $162 $52–$583 $164
2025 $5,539 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $3,297 117 payments
  2. Janssen Biotech, Inc. $1,598 61 payments
  3. AstraZeneca Pharmaceuticals LP $1,401 44 payments
  4. Pfizer Inc. $1,270 57 payments
  5. Incyte Corporation $1,132 39 payments
  6. GlaxoSmithKline, LLC. $1,058 39 payments
  7. Merck Sharp & Dohme Corporation $1,048 48 payments
  8. Gilead Sciences, Inc. $1,023 28 payments
  9. Seattle Genetics, Inc. $847 32 payments
  10. Daiichi Sankyo Inc. $836 33 payments
  11. Other $14,842 584 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $26,103 1,057 payments
  2. Long term medical supply or device loan $1,531 17 payments
  3. Education $720 8 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,899 48 payments
  2. KEYTRUDA $1,048 48 payments
  3. MONJUVI $791 26 payments
  4. BRUKINSA $745 27 payments
  5. LIBTAYO $685 28 payments
  6. Trodelvy $676 15 payments
  7. Lenvima $674 23 payments
  8. DARZALEX $666 23 payments
  9. CALQUENCE $570 16 payments
  10. ADCETRIS $560 25 payments
  11. Other $24,714 1,068 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

343

Median for Nurse Practitioner: 389

Drug cost

$16,835

Median for Nurse Practitioner: $21,885

Branded share of claims

27.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 18 $11,110
Dexamethasone Generic 52 $1,365
Potassium Chloride Generic 11 $1,251
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $643
Hydroxyurea Generic 27 $461
Ondansetron Odt Ondansetron Brand 34 $451
Triamcinolone Acetonide Generic 21 $363
Promethazine Hcl Generic 18 $211
Anastrozole Generic 11 $203
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 20 $175

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 94 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
$286 — —
VONJO
$238 — —
ENHERTU
$193 — —
KEYTRUDA
$192 — —
BRUKINSA
$185 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 94 with Patron

Records

1,082 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Neuroscience in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record